Tubulin inhibitors as dual targeting small molecules for cancer therapy [49] have been reported; e.g., the dual-targeting inhibitor of tubulin and Src kinase 12 [50] and the hydroxamic acid based microtubule destabilising agent 13 [51]; 14 synergistically targets both the tubulin colchicine site and aryl hydrocarbon receptor [52], and 15 is a dual inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) and tubulin [53] (Figure 2). This evidence concerns the gene PARP1 and cancer.